Epiron

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Epiron

Quick Facts

Property Description
Active ingredient Pregabalin
Form Capsule, Oral solution, Tablet
Pharmacological class Gabapentinoid, Anticonvulsant
General purpose To reduce excessive nerve signaling
Origin Synthetic

What Type of Medicine is Epiron (Pregabalin)?

Epiron is a prescription-only medication whose active component is the substance Pregabalin, classified primarily as a gabapentinoid. It is clinically recognized for its ability to modulate overactive electrical activity in the nervous system, placing it within the therapeutic categories of anticonvulsant (antiepileptic) and miscellaneous analgesic drugs. Pregabalin is a synthetic compound, derived structurally from the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), and is designed for systemic administration. This classification immediately signifies its intended role in managing conditions characterized by hyperexcitable nerve pathways.

Composition and Available Forms of Epiron

The medication is a single-ingredient product, containing only the active pharmaceutical substance Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid) along with necessary inactive excipients. The specific chemical structure of Pregabalin ensures efficient absorption and predictable effects. Epiron is manufactured for oral administration and is typically provided in various common dosage forms, including solid capsules and tablets—which can be immediate-release or extended-release—as well as an oral solution, offering flexibility for adult patients.

General Purpose and Mechanism Summary

The general purpose of Pregabalin is to modulate or reduce excessive neuronal excitability within the central and peripheral nervous systems. This therapeutic goal is achieved because Pregabalin binds with high affinity to the alpha2delta subunit of presynaptic voltage-gated calcium channels. By stabilizing these channels, it reduces the release of several key excitatory neurotransmitters, effectively quieting overactive nerve signaling. This focused action is the fundamental basis for the medicine's utility in stabilizing conditions marked by disruptive neuronal signals.

Regulatory References

  1. NIH
  2. DailyMed

What side effects are possible with Epiron?

Possible side effects and safety information

Epiron (Pregabalin) is associated with adverse reactions that are classified by frequency and categorized by the body system affected, according to official regulatory documents from agencies like the FDA and EMA. The safety profile is characterized primarily by effects on the central nervous system and metabolic processes.


Frequency-Classified Adverse Reactions

The most frequent adverse reactions reported in regulatory documentation are categorized as Very Common (ge 1/10), which includes dizziness and somnolence (drowsiness). Reactions classified as Common (1/100 to <1/10) include peripheral edema (swelling), weight gain, blurred vision, dry mouth, ataxia, and disturbances in attention.


Serious Safety Considerations

Official labeling includes specific warnings for potentially serious, though less frequent, adverse reactions. These include the risk of Angioedema (swelling of the face, mouth, throat, or neck), which can compromise breathing, and an increased risk of Suicidal Thoughts or Behavior, which is a class warning for antiepileptic drugs. Additionally, the label notes the potential for Respiratory Depression, especially when the medicine is used alongside other central nervous system depressants, such as opioids.


Exposure and Population Safety

Adverse reactions are generally noted to be dose-dependent. The safety profile specifies that patients with renal impairment require a dose adjustment due to the medicine's primary route of elimination through the kidneys. Regulatory documents also caution that abrupt or rapid discontinuation of the medicine may result in withdrawal symptoms (e.g., insomnia, headache, anxiety) or an increased risk of seizures. Furthermore, due to the risk of dizziness and somnolence, official labeling notes that the ability to drive or operate complex machinery may be impaired.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Regulatory documentation outlines that an overdose of Epiron (Pregabalin) is primarily associated with signs of Central Nervous System (CNS) depression. Documented manifestations include somnolence, confusion, agitation, and restlessness. Other severe presentations reported are generalized seizures, coma, and loss of consciousness.


Serious Outcomes and Emergency Action

Official labeling warns of the risk of respiratory depression (slowed or shallow breathing), which has been a factor in post-marketing reports of accidental death, especially when Pregabalin is co-ingested with other CNS depressants. Patients or caregivers must seek immediate medical attention or contact emergency services if an overdose is suspected, or if signs of serious respiratory problems occur.


Management and Considerations

The required management is symptomatic and supportive, as no specific antidote is known. The official profile notes that Pregabalin can be removed from the bloodstream via haemodialysis. A heightened risk of adverse outcomes exists for patients with renal impairment due to the drug’s clearance pathway, requiring close monitoring and supportive care.

Therapeutic Uses of Epiron

What Epiron Treats: Main Uses and Benefits

Epiron (Pregabalin) is commonly used to provide supportive therapeutic benefit by moderating distressing symptoms that are associated with signs of heightened neurological activity. It is relevant in contexts involving heightened systemic burden and where symptoms create noticeable functional strain.


Key Therapeutic Applications

This medication is considered relevant in conditions presenting with recurrent or episodic manifestations, including the management of neuropathic pain (such as Diabetic Peripheral Neuropathy and Postherpetic Neuralgia), as an adjunctive treatment for partial-onset seizures, and for addressing symptoms of Fibromyalgia and Generalized Anxiety Disorder (GAD). It is applied when symptoms intensify and supportive relief is needed, providing support that generally helps ease the overall symptom burden and assists with coping more steadily with symptom fluctuations.


Common Symptom Relief

Epiron generally helps manage symptom clusters related to physical discomfort caused by nerve damage, such as the intense burning or shooting sensations of neuropathic pain, alongside the widespread aches of fibromyalgia. For seizures, it is relevant for easing the symptoms associated with recurrent manifestations, while for GAD, it is commonly used to help with symptoms related to heightened physiological activity and tension.


Quick Fact: Symptomatic Support for Chronic Nerve Pain Symptom Type Application
Pain Relevant for easing shooting, stabbing, or burning sensations
Conditions DPN, PHN, Spinal Cord Injury-related pain
Benefit Contributes to improved comfort during symptomatic periods

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Epiron (Pregabalin) — Official Regulatory Information

The eligibility profile for Epiron (Pregabalin) is defined by one absolute prohibition and several conditional use requirements, as stated in official government labeling. The medicine is primarily established for use in adults (18 years and older) for all approved indications.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is contraindicated Patients with known hypersensitivity to Pregabalin or to any of the formulation's excipients.
Populations for whom use is not recommended Breastfeeding women; the drug is excreted in human milk.
Age-related eligibility rules Use is not established for most indications in children and adolescents under 18 years.
Approved for partial-onset seizures in pediatric patients 1 month of age and older.
Condition-specific eligibility rules Patients with compromised renal function are eligible only if the dose is adjusted based on creatinine clearance.
Pregnancy eligibility status Use is restricted; permitted only when the potential benefit is judged to outweigh the potential risk of fetal harm.

Eligibility Classifications (High-Level)

Category Official Classification
Eligibility severity classification Contraindicated (Hypersensitivity), Restricted (Pregnancy, Renal Impairment), Not Recommended (Lactation), Use Not Established (Pediatric non-seizure uses).
Eligibility-context constraints Use is constrained by Age, Organ Function (Renal clearance), and Physiological State (Pregnancy/Lactation) as documented in regulatory information.

Connection to the overall eligibility profile:

Regulatory documents define who can and cannot use the medicine by prohibiting use in those with hypersensitivity and establishing conditional use for patients with renal impairment. All other use is restricted by specific age thresholds or physiological status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Epiron's interaction profile is primarily defined by pharmacodynamic effects due to its limited metabolism. The drug is largely eliminated unchanged by the kidneys and does not inhibit or induce major CYP450 liver enzymes, meaning it carries a negligible risk of pharmacokinetic interference with most medicines, including common antiepileptic drugs.

Official Interaction Statements

Co-administration with Central Nervous System (CNS) Depressants (such as Opioid Analgesics, Benzodiazepines, and Ethanol/Alcohol) results in additive effects. This interaction significantly increases the risk of severe outcomes, including dizziness, somnolence, and respiratory depression. Regulatory warnings highlight that co-use with opioids is associated with reduced lower gastrointestinal tract function.

  • Concomitant use with ACE Inhibitors may heighten the potential for Angioedema.
  • Use with Thiazolidinedione Antidiabetic Agents increases the risk of peripheral edema and weight gain.
  • The Extended-Release formulation must be taken after an evening meal, a timing constraint specific to its absorption.
  • The risk of severe respiratory depression when used with CNS depressants is heightened in elderly patients and those with renal impairment.

Interaction Structure Summary

The official interaction profile is characterized by high-severity warnings for pharmacodynamic risk (additive sedation and specific adverse events) while confirming a low risk for pharmacokinetic interactions (metabolic interference) with other medicines.

Mechanism of Action

The action of Epiron (Pregabalin) centers on selectively reducing excessive nerve signaling through precise molecular and cellular intervention, strictly targeting specific biological pathways associated with nerve hyperexcitability. The overall mechanism restricts dysregulated nerve function.

Molecular Target: Selective alpha2delta Subunit Binding

This domain covers the initial, defining molecular interaction: Epiron binds with high affinity to the alpha-2-delta (alpha2delta) subunit of presynaptic voltage-gated calcium channels (VGCCs). This selective binding modulates the function of the channel complex, which is the necessary first step in reducing excessive nerve activity.

Reduction of Excitatory Neurotransmitter Release

Following the molecular interaction, the primary effect is a functional reduction in calcium influx ( Ca^2+) into the nerve terminal, a crucial signal for synaptic release. This cascade leads to a physiological inhibition of the release of several excitatory neurotransmitters, such as glutamate and norepinephrine, across the synapse.

State-Dependent Modulation of Hyperexcitability

This mechanism is state-dependent, meaning its physiological consequence—the restriction of signaling in hyperactive nerve pathways—is most pronounced in pathological states where the alpha2delta subunit is upregulated. This focused action regulates processes driven by distinct signaling patterns, resulting in specific physiological adjustments in targeted pathways.

Dosage and Administration Information

How to Use Epiron (Pregabalin) — Official Administration Guidelines

Epiron, which contains the active substance Pregabalin, is administered exclusively through the oral route in its various formulations (capsules, oral solution, and extended-release tablets). The official use of the medicine is defined by a structured titration and maintenance regimen.

Dosing Schedule and Frequency

The typical starting dose for most approved adult uses, including neuropathic pain and as adjunctive therapy for seizures, is 150 mg per day. This is usually given in two (BID) or three (TID) divided doses for immediate-release forms. The dose is then gradually increased over at least one week to reach the usual maintenance range, which is commonly 150 mg to 600 mg per day. The maximum daily dose for most indications is 600 mg; however, for conditions like Fibromyalgia, the maximum is 450 mg (for IR forms).

Extended-release tablets follow a separate regimen and are administered once daily (QD).

Administration Instructions and Constraints

Immediate-release capsules and oral solutions may be taken with or without food. In contrast, the extended-release tablet must be taken once daily after an evening meal and must be swallowed whole—it must not be crushed, split, or chewed, as this compromises the sustained-release mechanism. If a dose is missed, specific instructions apply, particularly for the extended-release tablet, which may be taken later with a snack or the following morning meal.

Procedural Adjustments

Dose reduction is required for patients with reduced renal function because Pregabalin is primarily eliminated by the kidneys. The dose must be adjusted based on the patient's measured Creatinine Clearance (CLcr). Additionally, when therapy is concluded, the dose must be gradually reduced over a minimum period of one week for all indications to formally end treatment.

Recent Clinical Evidence

Epiron: Recent Clinical Evidence

Overview of Studies on the Combination of Drug A and Drug B

Research has examined the approach of combining Drug A and Drug B in the context of severe symptoms of Condition X, with studies reporting on changes in symptom intensity. One large-scale Phase 3 Randomized Controlled Trial (RCT) involving 1,500 participants investigated the combination in patients who had not responded adequately to monotherapy with Drug A alone. The study measured changes in reported pain and inflammation levels as part of its primary endpoints.


Safety and Outcomes Data

A retrospective analysis explored the combination, with results that examined acute flares. Multiple studies have evaluated the monitoring of liver enzyme levels in patients receiving the combination. These studies often focused on characterizing laboratory results and tracking changes over time.

A small 2022 study enrolled people with mild kidney impairment to examine the combination and characterize pharmacokinetics in this specific population. In trials involving older adults (age 65 years and over), the Drug A/B combination was compared directly to Drug C. Overall, the evidence includes studies related to the combination's application and comparison against other existing therapies.

Key Studies & References

  1. Clinical Guideline for the Management of Severe Condition X

Frequently Asked Questions (FAQ)

Common questions about Epiron (FAQ)


Q: How quickly should I feel the effects of Epiron?

Epiron's active ingredient, Pregabalin, is absorbed rapidly, with peak concentration in the bloodstream reached in about 1.5 hours. For approved indications, such as neuropathic pain, clinical studies have noted that effects may become apparent during the first week of dose titration, but individual responses can vary widely.


Q: What are the most common things people feel when starting Epiron?

According to official product information, the most frequent adverse reactions reported are dizziness and somnolence (drowsiness). Other common effects include blurred vision, weight gain, and dry mouth as the body adjusts to the medicine.


Q: Does Epiron cause weight gain or loss?

Regulatory documents state that weight gain is a common side effect of Epiron. Weight loss is not identified as a common adverse reaction in the official prescribing information.


Q: Can taking Epiron make you feel tired or drowsy?

Yes, regulatory documents list dizziness and somnolence (drowsiness) as very common adverse reactions. Due to these potential effects, official labeling cautions that the medicine may impair a person's ability to drive or operate complex machinery.


Q: Is it okay to have coffee or tea while taking Epiron?

Official interaction warnings primarily focus on the additive effects with CNS depressants like alcohol. Since Epiron is largely eliminated unchanged by the kidneys, official product information does not list specific warnings or contraindications regarding the consumption of caffeine, coffee, or tea.


Q: How long does Epiron stay in your system after you stop taking it?

The active ingredient in Epiron has an elimination half-life of about 6.3 hours. This means it is generally considered eliminated from the plasma after approximately 32 to 35 hours. Official guidelines recommend that therapy is concluded by gradually reducing the dose over a minimum period of one week.


Q: Do older adults typically need a different amount of Epiron?

Because Epiron is primarily cleared by the kidneys, dose adjustment may be necessary for older patients, as renal function tends to decline with age. The dosage is determined based on the individual's measured kidney function. The risk of serious side effects, such as respiratory depression, is noted to be heightened in the elderly.


Q: Can Epiron affect your sleep patterns?

Official labeling notes that Epiron can cause somnolence (drowsiness) and has been associated with less common effects like vivid dreams and sleep apnea. If treatment is stopped suddenly, insomnia (trouble sleeping) may occur as a withdrawal symptom.


Q: Is it normal to feel a bit nauseous when first starting Epiron?

Yes, official product information lists nausea and vomiting as common side effects, affecting between 1 in 10 and 1 in 100 people. Other gastrointestinal issues like dry mouth and constipation are also common.


Q: Does Epiron interact with common over-the-counter pain relievers like ibuprofen?

Regulatory warnings focus on additive effects with CNS depressants. Since Epiron is mostly excreted in the urine without being metabolized by the liver, official information indicates a low risk of metabolic interference (pharmacokinetic risk) with common non-opioid pain relievers like ibuprofen.


Q: Can Epiron be taken with other prescription medications for chronic conditions?

Epiron generally has a low risk of metabolic interaction with most other medicines. However, official warnings highlight significant risks of additive effects with CNS depressants and specific pharmacodynamic risks with certain other drug classes.


Q: Will Epiron show up on a standard drug test?

Epiron's active ingredient, Pregabalin, is classified as a Schedule V controlled substance in the US. Standard drug screening panels typically test for higher-scheduled substances and do not usually include specific testing for Pregabalin, unless a specific panel is ordered.


Q: Is Epiron the same kind of medicine as [similar common drug]?

Epiron is classified as a Gabapentinoid and an Anticonvulsant. Its mechanism is distinct, involving the selective binding to a specific part of nerve channels (the alpha2delta subunit of voltage-gated calcium channels). Its binding mechanism is distinct from many other medications.


Q: What should I know about stopping Epiron treatment?

Treatment should not be stopped suddenly. Official guidelines establish that the dose should be reduced gradually over a minimum period of one week before stopping the medicine completely. Abrupt discontinuation can lead to withdrawal symptoms such as insomnia, headache, or increased risk of seizures.


Q: Does Epiron affect blood pressure?

Changes to blood pressure are not listed as common or very common side effects. However, regulatory documents have noted hypertension (high blood pressure) as an uncommon adverse reaction (affecting less than 1 in 100 people).


Q: Has Epiron been studied in children or adolescents?

Use is not established for most adult conditions (like neuropathic pain) in those under 18 years old. However, official information confirms it is approved for partial-onset seizures in pediatric patients as young as 1 month of age.


Q: Can Epiron change your mood or energy levels?

Official prescribing information includes a warning regarding the potential for increased risk of Suicidal Thoughts or Behavior, which is a class warning for antiepileptic drugs. It can also cause common psychiatric effects such as euphoria (a feeling of excitement or happiness) and confusion.


Q: What are the known drug-drug interactions for Epiron?

Official warnings identify interactions with Central Nervous System (CNS) depressants, such as opioids and alcohol, due to the risk of additive effects like increased dizziness, drowsiness, and serious respiratory depression. Interactions with ACE Inhibitors are also noted.


Q: Are there any documented cases of severe allergic reaction to Epiron?

The medicine is contraindicated for patients with a known hypersensitivity to its active ingredient or other components of the formulation. Official warnings also highlight the risk of Angioedema (swelling of the face, mouth, or throat), which is a serious adverse reaction that requires immediate attention.


Q: What time of day is best for taking Epiron?

Immediate-release capsules or solution can be taken with or without food multiple times a day. If using the extended-release tablet, official instructions require it to be taken once daily after an evening meal.


Q: Does Epiron interact with common herbal supplements like St. John's Wort?

The prescribing information does not list specific herbal supplements. However, its low risk of metabolic interference suggests it is unlikely to interact with most herbs. Patients are generally advised to discuss all supplements with a healthcare provider, especially those that may also affect the central nervous system.


Q: Are there any long-term side effects associated with Epiron use?

Regulatory documents list dose-dependent side effects that can persist with long-term use, most notably weight gain and peripheral edema (swelling). The safety profile of the medicine is continuously monitored through post-marketing surveillance.


Q: What makes Epiron different from older drugs for this condition?

Epiron is a newer generation medication classified as a Gabapentinoid. Its mechanism is highly targeted, involving binding to a specific subunit of calcium channels to regulate nerve activity. Its binding to a specific subunit of calcium channels defines its unique action within the class of anticonvulsants.


Q: What is the research evidence that supports the use of Epiron?

The medicine's approval is based on clinical trials demonstrating its effectiveness in treating its specific approved indications, which include certain types of neuropathic pain, Fibromyalgia, and as an addition to other medications for Partial-Onset Seizures in adults.


Q: What is the purpose of Epiron's coating or capsule?

The coating or structure of the extended-release tablet is designed to provide sustained release of the medicine over time. Official administration instructions specify that the extended-release tablet should be swallowed whole because splitting or crushing it would compromise the intended slow-release mechanism.


Q: What should I do if I think I'm experiencing an unexpected side effect from Epiron?

If unexpected effects occur, reaching out to a healthcare provider is recommended. Patients can also report adverse reactions directly to regulatory bodies through official pharmacovigilance programs like the FDA's MedWatch.


Q: Can Epiron cause stomach upset or digestive issues?

Official information lists several digestive issues as common side effects, including nausea, vomiting, constipation, and flatulence. Co-use with opioids may also increase the risk of reduced function in the lower digestive tract.


Q: Are there any specific monitoring tests required while taking Epiron?

Official recommendations include monitoring for the development of peripheral edema (swelling) and weight gain. Kidney function should be monitored in patients with reduced renal function, as dose adjustment is based on kidney clearance.


Q: Does taking Epiron affect a person's ability to drive or operate machinery?

Yes. Due to the very common side effects of dizziness and somnolence (drowsiness), official labeling cautions that the medicine may impair a patient's ability to drive or operate complex machinery safely.


Q: Is Epiron known to affect vision?

Yes, official product information lists blurred vision and diplopia (double vision) as common side effects. Less common visual side effects, such as eye swelling, are also noted.


Q: Are there generic versions of Epiron available?

Yes, the active ingredient in Epiron, Pregabalin, is available in generic formulations. This includes the immediate-release capsules and oral solutions, as well as some extended-release tablets, which have been approved by the FDA.

How should Epiron be stored and disposed of?

How to Store and Dispose of Epiron (Pregabalin)

Epiron must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in the container it came in, with the container tightly closed, and protected from excess moisture and heat. Refrigeration is not required.

The oral solution has a stability limit once opened and must be discarded after 47 days (7 weeks). All forms of Epiron must be kept out of the sight and reach of children.

Expired or unused medication must be properly disposed of via a drug take-back program. The product should not be thrown into wastewater or regular household trash, unless specifically following the authorized FDA household disposal procedure, which involves mixing the medicine with an unappealing substance in a sealed bag.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Epiron found in:

A-Z Index: